Please Wait
Applying Filters...
menu
    • menu
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Ropeginterferon ALFA-2B

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    PharmaEssentia Gets Taiwan Approval for BESREMi in ET
    PharmaEssentia Gets Taiwan Approval for BESREMi in ET

    10 Jun 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7543514

    FIRSTWORD PHARMA
    10 Jun 2026
    Share Share
    PharmaEssentia to Present Ropeginterferon Data at ASCO and EHA
    PharmaEssentia to Present Ropeginterferon Data at ASCO and EHA

    22 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-22/pharmaessentia-to-present-new-clinical-data-supporting-the-use-of-ropeginterferon-alfa-2b-in-essenti

    PHARMIWEB
    22 May 2026
    Share Share
    PharmaEssentia Reveals Japan Approval For High-Dose BESREMi
    PharmaEssentia Reveals Japan Approval For High-Dose BESREMi

    02 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-02/pharmaessentia-announces-japan-approval-of-high-dose-dosing-regimen-for-besremi

    PHARMIWEB
    02 Mar 2026
    Share Share
    Pharmaessentia To Build U.S. Plant In Puerto Rico For Besremi®
    Pharmaessentia To Build U.S. Plant In Puerto Rico For Besremi®

    09 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-09/pharmaessentia-announces-plans-to-establish-new-us-manufacturing-facility-in-puerto-rico-to-suppor

    PHARMIWEB
    09 Feb 2026
    Share Share
    PharmaEssentia’s BESREMi Added to Guidelines for Thrombocythemia
    PharmaEssentia’s BESREMi Added to Guidelines for Thrombocythemia

    27 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260127377586/en/PharmaEssentia-Announces-Updated-NCCN-Clinical-Practice-Guidelines-Include-ropeginterferon-alfa-2b-njft-BESREMi-for-Treatment-of-Essential-Thrombocythemia-ET

    BUSINESSWIRE
    27 Jan 2026
    Share Share
    FDA Sets August 30, 2026 PDUFA Goal Date For Ropeginterferon
    FDA Sets August 30, 2026 PDUFA Goal Date For Ropeginterferon

    13 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-13/fda-confirms-a-pdufa-goal-date-of-august-30-2026-for-the-sbla-submission-of-ropeginterferon-alfa-2b

    PHARMIWEB
    13 Jan 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.